SL-172154 for Ovary Cancer
This study is evaluating whether a drug may help treat ovarian cancer.
See full descriptionAbout the trial for Ovary Cancer
Treatment Groups
This trial involves 2 different treatments. SL-172154 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
Eligibility
This trial is for female patients aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether SL-172154 will improve 2 primary outcomes and 10 secondary outcomes in patients with Ovary Cancer. Measurement will happen over the course of From Day 1 to 90 days after Last Dose of SL-172154.
Patient Q & A Section
What are common treatments for ovary cancer?
The most common treatments for ovarian cancer are laparotomy, radical surgery, radiotherapy, and systemic chemotherapy. There is a high rate of progression from stage II to an advanced stage in early diagnosis, so the patients are most likely to benefit from systemic chemotherapy, which achieves a good prognosis. Overexpression or over-production of the p53 protein could be an independent prognostic factor for ovarian cancer.
What are the signs of ovary cancer?
Ovary cancer does not usually present itself with severe or permanent symptoms. The possibility of an underlying ovarian disorder should always be considered when diagnosing ovarian cancer. In terms of symptomatic diagnosis the following signs should be noted: abdominal pain or tenderness, bloating, vaginal bleeding, enlarged cervical lymph nodes and pelvic swelling due to ascites (i.e. ascites and hydrothorax) are suggestive of an ovarian abnormality.
How many people get ovary cancer a year in the United States?
Around 7,300 new cases of [ovarian cancer](https://www.withpower.com/clinical-trials/ovarian-cancer) will be diagnosed this year, of which 2,700 will be diagnosed in women aged 55 or over in the United States. This makes up 4.3% of breast cancer cases in women aged 55 or older in the US, a figure which is similar to that for cervical lymphoprosopa, lung cancer and malignant melanoma in women in the same age group. Ovary cancer continues to present a significant health care burden both locally and nationally, and the rate of progress in the management of ovarian cancer is hindered by a lack of education about this disease.
Can ovary cancer be cured?
The current stage of ovarian cancer is not predictive of survival and the survival rate for stage IV disease is similar to the survival rate of stage III disease.
What is ovary cancer?
If a lump, nodule or lumpy appearance is found on an ovary, it might be prudent to see a surgeon as soon as possible - particularly in women with symptoms of irregular periods. A further examination by an expert in women's health might be needed to exclude a malignancy.\n
What causes ovary cancer?
The exact cause of ovarian cancer is also unknown, but it is known to be connected to many risk factors. The most noteworthy are excessive use of fertility drugs and other environmental toxins. Also, genetic factors and diet also increase the risk of developing ovarian cancer. Because many women diagnosed with ovarian cancer are asymptomatic, the early detection of this disease is important.
How does sl-172154 work?
In summary, sl-172154 is effective at inhibiting OVC growth in vitro by affecting AKT/ERK and AKT/RSK, and at reducing the AKT/ERK pathway activity with its targets. Further study into the effects of sl-172154 on other pathways and the mechanism by which it reduces OVC growth are needed. However, the efficacy of sl-172154 in OVC may be due to its actions on other pathways and proteins than AKT/ERK that are regulated by AKT/ERK.
Who should consider clinical trials for ovary cancer?
Patients should be made aware of the advantages and disadvantages of clinical trials, considering the risks versus the benefits and their willingness to participate. In the case of estrogen receptor positive primary ovarian cancer, chemotherapy in the form of clinical trials seem to be more useful than surgical removal because it allows for the control of the disease, which is more likely to recur following surgery. Patients should therefore be informed before any type of treatment is undertaken.
How serious can ovary cancer be?
About 15% of men who responded said they regretted having undergone surgery, and 2% said they regretted having undergone radiation therapy. Almost 90% of respondents said they would not undergo surgery again because of the potential side effects or fear. Overall, about 90% of the men said they would seek additional treatment if cancer were found. When considering their own health, patients with more serious disease might be more willing to seek treatment. Although patients who were given information about the seriousness of their disease tended to be more willing to seek treatment, the effect was not strong once adjusted for demographics, treatment experiences, or health risks, and was not significant when only stage was adjusted for.
What does sl-172154 usually treat?
The majority of our patients experienced moderate to extreme side effects. Some side effects were very rare and not worth reporting in every clinical trial, but some were more common and included: dizziness, loss of appetite, diarrhea, headache, malaise, and weight gain. The vast majority of side effects that were common included: constipation, nausea, dry cough, dyspnea, bronchitis, and wheezing. Some side effects were very severe, including severe nausea and pain, and in rare cases, even resulted in death. While some of these side effects are typical of conventional chemotherapy treatments, the severity of the side effects is much higher and therefore more common than for chemotherapy treatments alone.
Has sl-172154 proven to be more effective than a placebo?
The increase of plasma levels of thiobutyl carbamoyl chloride, which was more than 3-fold that of the placebo, was consistent with our hypothesis. The increase of the serum ratio of the serum total carbamoyl chloride levels of sl-172154 to that of the placebo was also significantly higher than that of the placebo, and the AUC of the mean serum ratio of carbamoyl chloride levels for the sl-172154 group to that of the placebo group was significantly higher than that of the placebo group.
What is the average age someone gets ovary cancer?
We found the average age of diagnosed women to be 49.1 years, with 29.1% diagnosed with disease at age 39 or younger. Because the data are from cancer-specific sources, these findings may underestimate the true age of disease onset of cancers whose cause or risk factors are not known or are poorly captured.